George Mulligan,Barbara M. Bryant,Michael P. Morrissey,Andrew Bolt,Andrew I. Damokosh
申请号：
US15080709
公开号：
US20170023577A1
申请日:
2016.03.25
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
